MSC Exosomes for Alzheimer’s and Parkinson’s Disease | BioRegenEx
Neurodegenerative diseases like Alzheimer’s and Parkinson’s represent some of the most urgent unmet needs in modern medicine. MSC-derived exosomes are among the most studied regenerative tools for neuroprotection and neural repair — with 6 published studies in BioRegenEx’s research library specifically addressing AD and PD mechanisms.
The Neurodegenerative Disease Crisis
Over 6.7 million Americans currently live with Alzheimer’s disease, and approximately 1 million live with Parkinson’s disease. Both conditions involve progressive neurodegeneration, neuroinflammation, and the loss of specific neural populations — processes that conventional pharmaceutical approaches have largely failed to halt or reverse.
MSC-derived exosomes represent a new class of biological tool that may address several of the root mechanisms in both diseases simultaneously, rather than targeting single molecular pathways.
Key Published Research: AD and PD
- Exosomes derived from MSCs repair a Parkinson’s disease model by inducing autophagy (PubMed)
- Exosomes: a novel therapeutic target for Alzheimer’s disease (PubMed)
- MSC-derived exosome: a promising alternative in the therapy of Alzheimer’s disease (PubMed)
- MSC-derived exosomes: a new possible therapeutic strategy for Parkinson’s disease (PubMed)
- The potential use of MSCs and their exosomes in Parkinson’s disease treatment (PubMed)
- View all neurodegenerative research in the BioRegenEx Research Library →
Mechanisms Being Investigated
- Autophagy induction: Studies show MSC exosomes activate cellular cleanup mechanisms that clear misfolded proteins like tau and alpha-synuclein.
- Neuroinflammation suppression: Exosome cargo modulates microglial activation states, reducing chronic CNS inflammation.
- Neurotrophic support: MSC exosomes deliver BDNF, GDNF, and other neurotrophic factors that support dopaminergic and cholinergic neuron survival.
- Mitochondrial rescue: Research indicates exosome-mediated improvement in mitochondrial function in aging and degenerating neurons.
Partner With BioRegenEx
Join licensed physicians across the US who use BioRegenEx research-grade MSC exosomes in their regenerative medicine practice.
Supporting Research & Related Applications
📚 Browse the MSC Exosome Research Library (102+ studies) →
- MSC Exosomes for Stroke Recovery →
- MSC Exosomes for Traumatic Brain Injury →
- MSC Exosomes & Autism Research →
Sourcing MSC exosomes for your practice? Partner with BioRegenEx →
Research-use-only. Not intended to diagnose, treat, cure, or prevent any disease.
Frequently Asked Questions
What are MSC-derived exosomes?
Mesenchymal stem cell (MSC)-derived exosomes are nanoscale extracellular vesicles (roughly 30–150 nm) that carry signaling cargo such as proteins, lipids, and microRNA. They are cell-free (acellular) — not stem cells — and are studied in research for their role in cell-to-cell communication. BioRegenEx supplies characterized, research-use-only MSC exosomes with per-lot documentation.
What does research explore about MSC exosomes and neurodegenerative disease?
MSC-derived exosomes and the MSC secretome have been studied in preclinical neurodegeneration research (including Alzheimer’s and Parkinson’s models) for neuroinflammatory and neurotrophic signaling. These are research observations, not clinical outcomes. Explore the studies in our Exosome Research Library.
Are MSC exosomes approved for Alzheimer’s or Parkinson’s?
No. MSC-derived exosomes are not approved by the FDA to diagnose, treat, cure, or prevent this or any condition, and are supplied for research use only (RUO). Nothing here is a treatment claim.
Provided for research and educational purposes. Materials are research-use-only and are not intended to diagnose, treat, cure, or prevent any disease.